Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

815 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial.
Cascinu S, Berardi R, Labianca R, Siena S, Falcone A, Aitini E, Barni S, Di Costanzo F, Dapretto E, Tonini G, Pierantoni C, Artale S, Rota S, Floriani I, Scartozzi M, Zaniboni A; Italian Group for the Study of Digestive Tract Cancer (GISCAD). Cascinu S, et al. Among authors: barni s. Lancet Oncol. 2008 Jan;9(1):39-44. doi: 10.1016/S1470-2045(07)70383-2. Lancet Oncol. 2008. PMID: 18077217 Clinical Trial.
Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study.
Cascinu S, Berardi R, Sobrero A, Bidoli P, Labianca R, Siena S, Ferrari D, Barni S, Aitini E, Zagonel V, Caprioni F, Villa F, Mosconi S, Faloppi L, Tonini G, Boni C, Conte P, Di Costanzo F, Cinquini M; Italian Group for the Study of Digestive Tract Cancer (GISCAD). Cascinu S, et al. Among authors: barni s. Dig Liver Dis. 2014 Feb;46(2):182-6. doi: 10.1016/j.dld.2013.09.020. Epub 2013 Nov 2. Dig Liver Dis. 2014. PMID: 24189171 Clinical Trial.
Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD).
Cascinu S, Graziano F, Ferraù F, Catalano V, Massacesi C, Santini D, Silva RR, Barni S, Zaniboni A, Battelli N, Siena S, Giordani P, Mari D, Baldelli AM, Antognoli S, Maisano R, Priolo D, Pessi MA, Tonini G, Rota S, Labianca R. Cascinu S, et al. Among authors: barni s. Ann Oncol. 2002 May;13(5):716-20. doi: 10.1093/annonc/mdf091. Ann Oncol. 2002. PMID: 12075739 Free article. Clinical Trial.
Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
Cascinu S, Labianca R, Catalano V, Barni S, Ferraù F, Beretta GD, Frontini L, Foa P, Pancera G, Priolo D, Graziano F, Mare M, Catalano G. Cascinu S, et al. Among authors: barni s. Ann Oncol. 2003 Feb;14(2):205-8. doi: 10.1093/annonc/mdg061. Ann Oncol. 2003. PMID: 12562645 Free article. Clinical Trial.
High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
Cascinu S, Scartozzi M, Labianca R, Catalano V, Silva RR, Barni S, Zaniboni A, D'Angelo A, Salvagni S, Martignoni G, Beretta GD, Graziano F, Berardi R, Franciosi V; Italian Group for the Study of Digestive Tract Cancer (GISCAD). Cascinu S, et al. Among authors: barni s. Br J Cancer. 2004 Apr 19;90(8):1521-5. doi: 10.1038/sj.bjc.6601752. Br J Cancer. 2004. PMID: 15083179 Free PMC article. Clinical Trial.
The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients.
Scartozzi M, Sobrero A, Gasparini G, Berardi R, Catalano V, Graziano F, Barni S, Zaniboni A, Beretta GD, Labianca R, Cascinu S; Italian Group for the Study of Digestive Tract Cancer. Scartozzi M, et al. Among authors: barni s. Oncology. 2005;68(2-3):212-6. doi: 10.1159/000086776. Epub 2005 Jul 7. Oncology. 2005. PMID: 16015036
Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial.
Cascinu S, Labianca R, Barone C, Santoro A, Carnaghi C, Cassano A, Beretta GD, Catalano V, Bertetto O, Barni S, Frontini L, Aitini E, Rota S, Torri V, Floriani I; Italian Group for the Study of Digestive Tract Cancer; Pozzo C, Rimassa L, Mosconi S, Giordani P, Ardizzoia A, Foa P, Rabbi C, Chiara S, Gasparini G, Nardi M, Mansutti M, Arnoldi E, Piazza E, Cortesi E, Pucci F, Silva RR, Sobrero A, Ravaioli A. Cascinu S, et al. Among authors: barni s. J Natl Cancer Inst. 2007 Apr 18;99(8):601-7. doi: 10.1093/jnci/djk131. J Natl Cancer Inst. 2007. PMID: 17440161 Clinical Trial.
Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the 'GISCAD-alternating schedule' study findings.
Mandalà M, Barni S, Floriani I, Isa L, Fornarini G, Marangolo M, Mosconi S, Corsi D, Rulli E, Frontini L, Cortesi E, Zaniboni A, Aglietta M, Labianca R. Mandalà M, et al. Among authors: barni s. Eur J Cancer. 2009 Jan;45(1):65-73. doi: 10.1016/j.ejca.2008.09.005. Epub 2008 Dec 8. Eur J Cancer. 2009. PMID: 19068274 Clinical Trial.
815 results